ClinicalTrials.gg
Drug

Mavorixafor clinical trials

Also written X4P-001 and AMD11070.

studies test it
16
open now
2
in phase 3
2
first study started
2004

How each study uses mavorixafor is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the mavorixafor studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
26 Apr 2024 · XOLREMDI · NDA 218709 (FDA, Drugs@FDA)
European Union
27 Apr 2026 · Xolremdi · EMEA/H/C/006496 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Mavorixafor
8

Development codes

X4P-001
11
AMD11070
7
AMD070
1

Studies by the year they started

15 studies that test it; most in 2016 (5)

Studies that test mavorixafor, by start year
YearStudies
20041
20051
20165
20191
20201
20212
20241
20252
20261

By phase

A phase 1/2 study counts in both.

Phase 1
12
Phase 2
7
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 14 · Other 2

X4 Pharmaceuticals (12) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Genzyme, a Sanofi Company (1) · Abbisko Therapeutics Co, Ltd (1)

Often tested with

Tested in the same studies.

Ibrutinib (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1, 1 in phase 3

Studies that test mavorixafor, phase 3 first.

Studies

Open first, then newest update. How each study uses mavorixafor is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 16

Codes

What other systems call mavorixafor · ClinicalTrials.gg INT004728

  • MeSH (NLM) C494414mavorixaforConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 0G9LGB5O2WMAVORIXAFORConfirmed FDA, NLM, Wikidata
  • Wikidata Q27074430mavorixaforConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C126660MavorixaforOne source FDA
  • DrugBank DB05501One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.